Explore Stanford technologies available for licensing:

Stanford researchers have found a way to isolate tiny regions of tissue directly from standard glass pathology slides for downstream analysis.

Stanford researchers have found a way to predict an individual's remaining lifespan directly from routinely collected longitudinal electronic health records, enabling faster and more accurate decision-making for life insurance underwriting, reinsurance, and clinical planning.

Stanford researchers have found a way to make laser output more stable and less noisy using a compact passive device.

Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.

Stanford researchers have developed a high-throughput platform that designs, delivers, and screens synthetic microRNAs to precisely reprogram human T cells and improve the efficacy of CAR T cell therapies.

Stanford researchers have created a next-generation platform for producing real meat without raising or slaughtering animals, using a combination of rejuvenated muscle cells and a fully edible, protein-rich scaffold.

Stanford scientists have developed a generative learning framework paired with a compact wearable EMG device that extrapolates limited sensor inputs to reconstruct muscle activity equivalent to that captured by high-density sensor arrays.

Stanford researchers have developed an innovative metasurface-enabled, CMOS-compatible platform for high-density, on-chip oligonucleotide synthesis that enables precise, site-selective DNA production without mechanical scanning or complex photolithographic alignment.

Scientists at Stanford have developed a new method to manufacture sterile microbial food that contains levels of key bioactive metabolites derived from fermented foods.

The blood-brain barrier (BBB) remains a major obstacle to developing effective therapies for neurological and neurodegenerative disease, because most drugs and biologics do not efficiently reach brain tissue.

Stanford researchers have developed REULR (Receptor Elimination by E3 Ubiquitin Ligase Recruitment), a mix and match nanobody (VHH)-based extracellular targeted protein degradation (eTPD) platform.

Stanford researchers have developed a macrophage-targeted PEGylated liposome ("PEGosome") platform that selectively delivers polyethylene glycol (PEG) to inflammatory monocytes and macrophages driving neuroinflammation in diseases such as multiple sclerosis (MS), Alzheimer's d

Researchers at Stanford have developed ComBind, a computational platform that improves prediction of how drug molecules bind to their protein targets by combining structural modeling with readily available binding data from other molecules.

Stanford scientists have established a modeling based proof-of-concept for a subsurface logging method that reliably distinguishes hydrogen from methane using thermal conductivity, overcoming a major limitation of existing oil-and-gas logging technologies.

Researchers at Stanford have created a de novo protein design platform that designs binding proteins specifically interacting with the MHC-peptide complex.